靶向胰高血糖素样肽-1/胰高血糖素/葡萄糖依赖性促胰岛素多肽受体的肥胖症新型治疗药物——retatrutide  

A novel obesity treatment drug targeting glucagon-like peptide-1/glucagon/glucose-dependent insulinotropic polypeptide receptor:retatrutide

作　　者：王文轩 冯东梅 程卯生[1] 刘洋[1] WANG Wen-xuan;FENG Dong-mei;CHENG Mao-sheng;LIU Yang(School of Pharmaceutical Engineering,Shenyang Pharmaceutical University,Key Laboratory of Target-based Drug Design and Research Discovery of Ministry of Education,Shenyang 110016,China)

机构地区：[1]沈阳药科大学制药工程学院基于靶点的药物设计与研究教育部重点实验室,沈阳110016

出　　处：《临床药物治疗杂志》2024年第4期17-20,共4页Clinical Medication Journal

摘　　要：肥胖症是一种由遗传、环境等因素引起的以脂肪过多为特征的复杂疾病。retatrutide(研发代号:LY3437943)作为一种胰高血糖素样肽-1/胰高血糖素/葡萄糖依赖性促胰岛素多肽受体激动剂,在肥胖症及心血管疾病治疗中显示出长期有效性。Ⅰ、Ⅱ期临床试验结果表明,retatrutide具有良好的有效性和安全性。该药物目前正在处于Ⅲ期临床试验的招募阶段。本文主要对该药物的基本信息、作用机制、临床前研究及临床研究等方面进行概述。Obesity is a complex disease characterized by excess adiposity caused by genetic and environmental factors.As a glucagon-like peptide-1 receptor/glucagon/glucose-dependent insulinotropic polypeptide receptor agonist,retatrutide(research code:LY3437943)has demonstrated long-term efficacy in the treatments of obesity and cardiovascular disease.The results of phaseⅠandⅡclinical trials showed that retatrutide had good efficacy and safety profiles.This drug is currently in the recruitment phase of phaseⅢclinical trials.This article provides an overview of the retatrutide's basic information,mechanism of action,pre-clinical studies and clinical studies.

关 键 词：retatrutide 肥胖症 2型糖尿病 奥利司他 

分 类 号：R977[医药卫生—药品]